CDC6 and cancer: The results were likely attributable to the higher CDC6 KO efficiency of the PAR‐Lipo complexes than of the other treatments in cancer cells, which was further confirmed by a western blot assay that indicated the lowest expression of CDC6 in the PAR‐Lipo complex‐treated group (Figure 5F).